Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Abcellera Biologics Inc ABCL

Healthcare Biotechnology
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.


NDAQ:ABCL - Post by User

Abcellera Biologics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(161)
•••
  • Bullknit101X
Post by Bullknit101on Jul 22, 2025 10:51pm
91 Views
Post# 36653332

The Palantir of Biologics ?

The Palantir of Biologics ?AbCellera has been referred to this. Can someone she some light on this? My only concern is timing. Phased trials take a while and they seem to be only starting phase 1. Lots of PhDs at the helm and very well run company but, just need to understand while retail investors are pilling into this. Arny Trezzi and Antonio Linares are both super bullish. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities